Home / Business and Economy / Boehringer Sales Surge: Jardiance Drives Growth
Boehringer Sales Surge: Jardiance Drives Growth
15 Jul
Summary
- First-half net sales reached 15.8 billion euros.
- Sales experienced a 16% increase, currency adjusted.
- Jardiance diabetes drug fueled significant sales growth.
Boehringer Ingelheim announced robust first-half net sales amounting to 15.8 billion euros. This represents a significant 16% increase when accounting for currency adjustments, underscoring the company's strong financial performance.
The success of its Jardiance diabetes medication was a primary contributor to this sales surge. The German pharmaceutical firm is leveraging this momentum to advance its product development pipeline.
Looking ahead, Boehringer Ingelheim is preparing to submit an application for U.S. approval of a new drug targeting obesity. This strategic move indicates the company's focus on expanding its therapeutic offerings and addressing unmet medical needs.
